Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Merit Medical Opens Hypotube Center of Excellence



Merit Medical Opens Hypotube Center of Excellence

New Center of Excellence Significantly Enhances Hypotube Manufacturing
Capabilities

SOUTH JORDAN, Utah, June 4, 2013 (GLOBE NEWSWIRE) -- Merit Medical Systems,
Inc. (Nasdaq:MMSI), a leading manufacturer and marketer of proprietary
disposable devices used primarily in cardiology, radiology and endoscopy today
announced the opening of a hypotube manufacturing Center of Excellence in
Galway, Ireland. The Center significantly enhances Merit's hypotube
manufacturing capabilities and includes best-in-class design and production
systems and advanced equipment and controls for producing customized hypotubes
for uses including percutaneous transluminal coronary angioplasty (PTCA)
balloon catheters. The Merit Hypotube^TM is sold by Merit Medical's Coatings
division.

"We've been coating and supplying hypotubes to the medical device OEM industry
for many years," said Fred P. Lampropoulos, Chairman and CEO of Merit Medical
Systems, Inc. "We made a commitment to become one of the world's leading
hypotube manufacturers and have invested in the new equipment and expertise to
do so."

Building on Merit Medical Coating's world-class PTFE wire and hypotube coating
platform technologies, the capabilities of the new Center of Excellence
include the newest and most precise laser cutting machines available for
custom spiral-cutting, skive-cutting and slot-cutting; laser ablation machines
for non-contact removal of coating from the hypotube surface; leak testing at
higher pressures; laser welding including seam-welding and point-welding of
stylets; an advanced, controlled inspection process to inspect the full
diameter and length of tubes; a cleaning process that does not require harsh
chemicals; passivation to add resistance to corrosion; and higher production
capacity. Merit Medical has also added a new customer-focused team to drive
strong development, partnership and supply.

A Center of Excellence designation refers to companies, facilities, or teams
within companies that promote collaboration to improve expertise through best
practices, research, and/or new technologies. For more information visit:
www.meritmedicalcoatings.com/takeanewlook.

ABOUT MERIT

Founded in 1987, Merit Medical Systems, Inc. is engaged in the development,
manufacture and distribution of proprietary disposable medical devices used in
interventional and diagnostic procedures, particularly in cardiology,
radiology and endoscopy. Merit serves client hospitals worldwide with a
domestic and international sales force totaling approximately 200 individuals.
Merit employs approximately 2,750 people worldwide with facilities in Salt
Lake City and South Jordan, Utah; Angleton, Texas; Richmond, Virginia;
Malvern, Pennsylvania; Maastricht and Venlo, The Netherlands; Paris, France;
Galway, Ireland; Beijing, China; Copenhagen, Denmark; and Rockland,
Massachusetts.

ABOUT MERIT MEDICAL COATINGS

Merit Medical Coatings (www.meritmedicalcoatings.com) is a medical device
component manufacturer and coating company. Merit Medical Coatings
manufactures medical device components including hypotube/catheter shafts,
guide wire components, needles and mandrels, and work with customers on custom
solutions from the design phase through finishing details including coiling,
laser cutting and ablation. Merit Medical Coatings is a world leader in the
application of PFOA-free, PTFE and hydrophilic coating options for bulk
quantities of medical wires and tubes. Merit Medical Coatings is a division of
Merit Medical Systems, Inc., (Nasdaq:MMSI).

Statements contained in this release which are not purely historical,
including, without limitation, statements regarding Merit's forecasted
revenues, net income, financial results or anticipated acquisitions, are
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995 and are subject to risks and uncertainties such
as those described in Merit's Annual Report on Form 10-K for the year ended
December 31, 2012. Such risks and uncertainties include risks relating to
Merit's potential inability to successfully manage growth through
acquisitions, including the inability to commercialize technology acquired
through recent, proposed or future transactions; product recalls and product
liability claims; expenditures relating to research, development, testing and
regulatory approval or clearance of Merit's products and risks that such
products may not be developed successfully or approved for commercial use;
greater governmental scrutiny and regulation of the medical device industry;
reforms to the 510(k) process administered by the U.S. Food and Drug
Administration; compliance with governmental regulations and administrative
procedures; potential restrictions on Merit's liquidity or its ability to
operate its business by its current debt agreements; possible infringement of
Merit's technology or the assertion that Merit's technology infringes the
rights of other parties; the potential of fines, penalties, or other adverse
consequences if Merit's employees or agents violate the U.S. Foreign Corrupt
Practices Act or other laws and regulations; laws targeting fraud and abuse in
the healthcare industry; potential for significant adverse changes in, or
failure to comply with, governing regulations; the effect of changes in tax
laws and regulations in the United States or other countries; increases in the
price of commodity components; negative changes in economic and industry
conditions in the United States and other countries; termination or
interruption of relationships with Merit's suppliers, or failure of such
suppliers to perform; fluctuations in Euro and GBP exchange rates; Merit's
need to generate sufficient cash flow to fund its debt obligations, capital
expenditures, and ongoing operations; concentration of Merit's revenues among
a few products and procedures; development of new products and technology that
could render Merit's existing products obsolete; market acceptance of new
products; volatility in the market price of Merit's common stock; modification
or limitation of governmental or private insurance reimbursement policies;
changes in health care markets related to health care reform initiatives;
failure to comply with applicable environmental laws; changes in key
personnel; work stoppage or transportation risks; uncertainties associated
with potential healthcare policy changes which may have a material adverse
effect on Merit; introduction of products in a timely fashion; price and
product competition; availability of labor and materials; cost increases;
fluctuations in and obsolescence of inventory; and other factors referred to
in Merit's Annual Report on Form 10-K for the year ended December 31, 2012 and
other materials filed with the Securities and Exchange Commission. All
subsequent forward-looking statements attributable to Merit or persons acting
on its behalf are expressly qualified in their entirety by these cautionary
statements. Actual results will differ, and may differ materially, from
anticipated results. Financial estimates are subject to change and are not
intended to be relied upon as predictions of future operating results, and
Merit assumes no obligation to update or disclose revisions to those
estimates.

CONTACT: Anne-Marie Wright, Vice President, Corporate Communications
         Phone: (801) 208-4167
         e-mail: awright@merit.com
         Fax: (801) 253-1688

company logo
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement